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Abstract
Background: Human mesenchymal stem cells (MSC) with the capacity to differentiate into
osteoblasts provide potential for the development of novel treatment strategies, such as improved
healing of large bone defects. However, their low frequency in bone marrow necessitate ex vivo
expansion for further clinical application. In this study we asked if MSC are developing in an
aberrant or unwanted way during ex vivo long-term cultivation and if artificial cultivation conditions
exert any influence on their stem cell maintenance. To address this question we first developed
human oligonucleotide microarrays with 30.000 elements and then performed large-scale
expression profiling of long-term expanded MSC and MSC during differentiation into osteoblasts.
Results: The results showed that MSC did not alter their osteogenic differentiation capacity,
surface marker profile, and the expression profiles of MSC during expansion. Microarray analysis
of MSC during osteogenic differentiation identified three candidate genes for further examination
and functional analysis: ID4, CRYAB, and SORT1. Additionally, we were able to reconstruct the
three developmental phases during osteoblast differentiation: proliferation, matrix maturation, and
mineralization, and illustrate the activation of the SMAD signaling pathways by TGF-β2 and BMPs.
Conclusion: With a variety of assays we could show that MSC represent a cell population which
can be expanded for therapeutic applications.
Background
In recent years mesenchymal stem cells (MSC) have gen-
erated a great deal of interest as a potential source for cell-
based therapeutic strategies. Human MSC are easy to iso-
late from small aspirate of bone marrow via their adher-
ence ability. These cells readily generate single-cell-
derived colonies that can be highly expanded and differ-
entiated into a variety of cell types, such as osteoblasts
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[5,6]. Further, human MSC can improve cardiac function
after infarction [7,8] or symptoms of bone and cartilage
defects [9-13], as well as neurodegenerative diseases such
as Alzheimer's [14-16]. Their efficiency in multiple types
of cellular therapeutic strategies has been demonstrated,
including applications in treating children with osteogene-
sis imperfecta [17], hematopoietic recovery [18], and bone
tissue regeneration [19,20]. Also first preclinical trails are
in progress to test their capacity and toxicity in applica-
tions for human treatment [21].
One great advantage of MSC is that these cells may be
directly obtained from individual patients, thereby elimi-
nating the complications associated with immune rejec-
tion of allogenic tissue and infectious diseases. However,
for cell therapies MSC have to be expanded and/or manip-
ulated to obtain a sufficient amount of cells that can be
subsequently used for treatment. Despite growing experi-
ence and knowledge concerning human MSC and their
use in cell-based strategies, the molecular mechanisms
that govern MSC self-renewal, expansion and multiline-
age differentiation are not well understood and remain an
active area of investigation.
In this study we asked if human MSC are developing in an
aberrant or unwanted way during ex vivo long-term culti-
vation and if cultivation conditions exert any influence on
their stem cell maintenance. To address this question sys-
tematically and comprehensively we first developed
human oligonucleotide microarrays with 30.000 ele-
ments and then performed large-scale expression profil-
ing of long-term expanded MSC isolated from clinically
relevant samples. We monitored these cells during their
expansion ex vivo with respect to proliferation kinetics,
surface marker profile and differentiation potential.
Finally we analyzed the gene expression profiles of MSC
during osteogenic differentiation. Our results showed that
expansion of MSC does not result in substantial genetic
and morphological aberrations. We illustrated for the first
time in a human model the three main stages of osteo-
genic development, and we could show the diverse regu-
lation of the SMAD pathways by TGF-β2 and BMPs.
Results
Human MSC maintain their undifferentiated phenotype 
during long-term expansion
The results of the ex vivo long-term expansion experiments
showed that the undifferentiated phenotype of MSCs is
maintained with respect to differentiation potential, sur-
face marker profile and gene expression profiles. At con-
fluence of 75–85% the cultivated cells were detached and
flow cytometry analysis were performed to verify the
purity of the cell population without any contaminations,
such as haematopoietic cells. Following surface marker
profile were detected: CD44+, CD90+, CD73+, CD105+,
CD166+, CD11b-, CD34-, CD45-, CD117-, HLA DR-. For
the subsequent experiments MSCs were expanded until
the end of the tenth passage. At the end of each passage
the cells were analyzed by flow cytometry and a cell aliq-
uot was seeded out for testing their differentiation ability.
Proliferation kinetics and differentiation potential
The growth kinetics of five donors was investigated from
the primary culture through the tenth passage, corre-
sponding to approximately 26 cell doublings. For recalcu-
lating the starting number of MSC in the MNC fraction,
CFU assays were performed and the MSC frequency was
determined. Primary cultures reached their first conflu-
ence from around 80% in about 2 weeks and about 10 cell
doublings. During the following passages the prolifera-
tion rate slowed down. During the whole expansion
period – starting with passage two until passage ten – in
every passage the osteogenic differentiation ability was
tested. The osteogenic differentiation was confirmed by
Alizarin Red S staining and Alkaline Phosphatase assay.
Throughout this examination period differentiation abil-
ity into osteoblasts was observed in low passages (passage
2, after 12 cell doublings) as well as in a higher passage
(passage 10, after 26 cell doublings), (Figure 1). MSC
expanded to approximately 26 cell doublings were able to
differentiate into adipocytes (Figure 1).
Surface marker profile
After the cultivation of MSC from the mononuclear cell
fraction (passage 0) and at the end of each individual pas-
sage, the MSC were analyzed by flow cytometry to moni-
tor the surface marker profile during their ex vivo
expansion. Each investigated passage depicted homoge-
nous cell population demonstrating that MSC did not
alter their physical and morphological properties during
high grade ex vivo expansion under the culture conditions
tested [see Additional file 1]. In addition to the examina-
tion of the surface marker profile, we also performed Real-
time RT-PCR Sybr™ Green I assays for stem cell specific
genes. The examined stem cell markers, CD44, CD73,
CD166, CD105, CD90 and STRO1 showed stable expres-
sion level during the whole expansion period proving the
results obtained by FACS analyses. As expected, CD34,
CD45 and TERT could not be detected on any examined
time point [see Additional file 2].
Large-scale gene expression profiling of MSC during ex vivo 
expansion
In order to monitor the molecular events that govern the
ex vivo expansion of undifferentiated MSC we performed
large-scale gene expression profiling using oligonucle-
otide microarrays with 29952 elements (ArrayExpress,
accession numbers A-MARS-2, E-MARS-5, and E-MARS-6,
[see Additional file 3, 4, 5]). After background correction,Page 2 of 15
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handling, 838 genes could be detected as differentially
expressed with at least 2-fold change, between cells from
passage 2 with cells from passage 5, and 345 genes, when
comparing passage 5 cells with passage 10 cells [see Addi-
tional file 6]. A modified version of the regularized t-test
[22] with the complete data set was performed to identify
significantly differentially expressed genes in ten exam-
ined donors (Nr. 1–10, passage 2 vs. passage 5) and five
examined donors (Nr. 6–10, passage 5 vs. passage 10).
The results showed that only 9 genes were significantly
differentially expressed (p < 0.05) during 8 cell doublings
Upper panel: Osteogenic differentiation of MSC after passage 2 (A, B) and passage 10 (C, D)Figure 1
Upper panel: Osteogenic differentiation of MSC after passage 2 (A, B) and passage 10 (C, D). Alizarin Red S staining and 
Alkaline phosphatase assay were performed after 21 days of osteogenic induction (d21).100× magnification. Middle Panel: 
Morphological alterations during osteogenesis determined by microscopy on the day of induction (d0), day 4, 7, 14 and 21 after 
induction. All pictures are shown in 100× magnification. Lower Panel: Adipogenic differentiation of MSC in passage 10 char-
acterized by Oil red O staining; (A) MSC not induced, undifferentiated; (B) MSC 21 days after induction with adipogenic 
medium 100× magnification.
Alizarin Red S staining
MSC of passage 2 MSC of passage 10
Alkaline phosphatase assay
MSC of passage 2 MSC of passage 10
Morphological alterations during osteogenesis
Evaluation of adipogenic differentiation ability after 26 cell doublings by Oil Red O staining
MSC on day of induction MSC on day 4 
after induction
MSC on day 7 
after induction
MSC on day 14 
after induction
MSC on day 21 
after induction
(A) Control, day 21 (B) Induced, day 21
(A) Control, day 21 (B) Induced, day 21 (A) Control, day 21 (B) Induced, day 21
(A) Control, day 21 (B) Induced, day 21 (A) Control, day 21 (B) Induced, day 21Page 3 of 15
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passage 5 (Table 1). Significantly differentially expressed
genes represent proteins with diverse functions: extracel-
lular matrix proteins (Col11A1, tenascin xb), proteins
involved in bone, fat and epithelial cell metabolism (oste-
oprotegerin, b219ob receptor, FGF- 7), pain perception
and stress response (proenkephalin), growth-promoting
activity (IGF-2), and signaling and cell survival mecha-
nisms (semaphorin 3c). The hypothetical protein
XP_016240 is annotated as similar to keratinocyte growth
factor-like protein, and the hypothetical protein
dkfz434b044 is defined as a cysteine-rich secretory pro-
tein containing LCCL domain 2. The expression data from
the above mentioned genes could be confirmed by inde-
pendent real-time RT-PCR [see Additional file 7].
In sum, these results show that long-term expansion of
MSC did not alter their differentiation potential, surface
marker profiles, and expression profiles.
Expression profiling of MSC during osteogenic 
differentiation reveals distinct phases of osteogenic 
development
Osteogenic differentiation
Human MSC from three different donors (Nr. 9–11) were
cultured until their fourth passage and were induced to
osteogenic differentiation at a confluence of 70–80%. The
osteogenic differentiation was observed during the whole
period by microscopy and was terminated on day 21 after
induction. First signs for calcification appeared as black
regions within the cell monolayer after around seven days.
The maximum of calcified extracellular matrix was
observed after 21 days of treatment (Figure 1). The oste-
oblast phenotype was confirmed by Alkaline Phosphatase
assay and Alizarin Red S staining (data not shown).
Expression of osteoblast specific marker genes
We performed Real-time RT-PCR assays to detect the
expression levels of osteoblast specific marker genes MSX2
(homeobox gene MSX2), VDR (vitamin D receptor),
COL1A1 (collagen 1A1), ALPL (alkaline phosphatase),
SPARC (osteonectin), SPP1 (osteopontin) and BGLAP
(osteocalcin) to prove the osteoblast phenotype. The log2
transformed results are shown in the supplementary
material [see Additional file 8].
The data obtained by Real-time RT-PCR showed the
expected expression profiles of the osteoblast phenotype.
ALPL showed the expected expression level progression.
Its expression was increased starting with day four of the
differentiation period and decreased after day 14 until day
21 during the mineralization phase. The homeobox gene
MSX2, which is implicated in osteoprogenitor cell func-
tion [23] and an up-stream regulator of RUNX2, which
was described to be important for the osteogenic differen-
tiation [24], were up-regulated during the whole period of
differentiation. COL1A1 is known to be an early marker of
osteoprogenitor cells [25]. Its maximum of expression
was reached on day 21. Also SPARC showed a nearly con-
stant, up-regulated expression level with its maximum on
day 21 of differentiation. SPP1 is an extracellular matrix
protein, known to peak twice in its expression [26]:
around day 4, during proliferation, and between days 14–
21, during mineralization. BGLAP was described as a late
marker of developing osteoblasts appearing with matrix
mineralization [27] and was maximally expressed on day
21. Interestingly, BGLAP was already significantly up-reg-
ulated on day four, whereas the mineralization could not
be observed before day seven.
Large-scale gene expression profiling of MSC during osteogenesis
The RNA was harvested at four time points during the dif-
ferentiation period and hybridized on human oligonucle-
otide microarrays. As reference, RNA harvested from MSC
one day before the osteogenic induction was used
(ArrayExpress, accession numbers A-MARS-2 and E-
MARS-3). After LOWESS-subgrid normalization and fil-
tering missing values 1108 genes were selected with two-
fold up- or downregulated expression in at least one time
point [see Additional file 9].
Correspondence between co-expressed genes and phenotypic 
changes
Differentially expressed genes were clustered according to
their expression profiles using the k-means clustering
method [28] [see Additional file 10]. The cluster analysis
was performed with at maximum 50 iterations and using
12 different clusters, each containing between 58 and 167
genes (Figure 2). The number of clusters was estimated by
FOM analyses [see Additional file 11]. Additionally, hier-
archical clustering was performed and the results were
comparable to k-means clustering [see Additional file 12].
By analyzing the genes of the different clusters and their
expression profiles, we were able to reconstruct three
main phases of osteogenic development (Figure 3): prolif-
eration, matrix maturation, and mineralization. Addition-
ally, novel candidate genes could be found which are not
known to play a role during osteogenic differentiation:
ID4 (inhibitor of DNA-binding), CRYAB (crystalline-αB)
and SORT1 (sortillin1). The expression of these genes was
subsequently confirmed by quantitative RT-PCR [see
Additional file 13].
For gene ontology (GO) analysis we categorized ESTs with
available RefSeq annotation (506 RefSeq annotations out
of 1108 differentially expressed genes) according to GO
terms for biological process (Figure 4), cellular compo-
nent, and molecular function [see Additional file 14]. In
detail, cluster 3 and 11 represented proliferation phasePage 4 of 15
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tion, regulation of cell cycle, metabolism and regulation
of transcription. Cluster 8 and 9 illustrated genes which
were up-or down regulated during the whole period of
differentiation. They describe the phase matrix matura-
tion and are involved in development, cell differentiation,
metabolism, regulation of DNA-dependent transcription.
The phase of mineralization is evident in cluster 7 and 12,
which include genes involved in signal transduction,
transport, metabolism, and development.
The GO analysis showed that genes found in cluster 2 and
6 were also involved in cell adhesion, signal transduction,
cell cycle, and regulation of transcription, similar to clus-
ter 3 and 11. Cluster 10 described genes of development
and metabolism among the rest. Cluster 1 and 5 com-
bined genes of cell adhesion, transport, cell proliferation
and regulation of transcription. Cluster 4 represented
genes associated with transport and regulation of tran-
scription.
In summary, GO annotation showed that nearly in each
cluster genes of cell adhesion, signal transduction, trans-
port, and regulation of transcription were present, illus-
trating the complex regulation of different events during
osteogenesis.
Pathway analysis of the expression data set
The data set of 1108 genes with significant up or down
regulation (+/- 2 fold, p ≤ 0.05) was mapped with the
Pathway Explorer on pathways derived from the Biocarta
and KEGG database [29,30]. In total 276 out of 1108
genes could be mapped with their available RefSeq num-
bers (24.9%). Only pathways where at least 10% and
more than five mapped genes could be found were
selected for further examination. Following these criteria
the TGF-β signaling pathway (12 mapped genes out of
116, 10.38%, see Figure 5) was ranked first, which sum-
marized the different Smad pathways regulated by the
members of the TGF-β family: BMP, TGF-β and inhibin.
Cell growth and proliferation is controlled by the mem-
bers of the TGF-β superfamily which includes structurally
related proteins like TGF-β, activins, and bone morphoge-
netic proteins (BMPs) [31-34]. In the here presented TGF-
β signaling pathway BMP2 and BMP6, MADH1 and
MADH9 (corresponding to SMAD1 and SMAD9) were
up-regulated and the inhibitor of DNA binding ID4 was
down-regulated (Figure 5). BMP2 and BMP6 are able to
bind to BMPR-type I and II, whereas BMP6 is able to bind
to ActRIIA [35,36]. Due to the binding of these two mole-
cules to the heterodimeric receptor complex the SMAD
signaling pathway is activated. Our data illustrated fur-
ther, that the inhibitor of DNA binding, ID4 was down
regulated and the osteogenic differentiation could be
induced. In parallel, TGF-β2, inhibin A and B were down-
regulated during the differentiation period, whereby the
following events were suppressed. Hence, under these
experimental conditions the Smad-signaling pathway
activated by BMP2 was responsible for the osteogenic
development. In contrast, the activation of the Smad path-
way by TGF-β and inhibin was suppressed.
In vivo relevance of human MSC as in vitro differentiation 
model
The in vitro differentiation of MSC into osteoblasts is often
used model to examine the regulation mechanisms dur-
ing osteoblast development. To evaluate the in vivo rele-
vance of this model, we compared the RNA obtained at
the diverse time points during osteogenic differentiation
with RNA isolated from primary cultures of normal non-
mineralized human osteoblasts derived from hipbone
using our microarrays (ArrayExpress, accession numbers
A-MARS-2, and E-MARS-4) [see Additional files 15, 16,
Table 1: Differentially expressed genes of MSC after high grade expansion.
Passage 2 vs passage 5 Acc.No Gene name log2 ratio Fold-change
XM_016240 hypothetical protein xp_016240; loc87477//Homo sapiens similar to 
keratinocyte growth factor-like protein, group II – human (LOC158116)
0.92 1.89
NM_006211_1 proenkephalin; penk 1.58 2.99
NM_001854_1 collagen, type xi, alpha 1; col11a1 1.27 2.41
BC010956_1 similar to fibroblast growth factor 7 (keratinocyte growth factor) 1.03 2.04
NM_000612_1 Insulin-like growth factor 2 (somatomedin A); igf2 1.59 3.01
NM_031476_1 hypothetical protein dkfzp434b044; dkfzp434b044 1.34 2.53
U52914_1 b219ob receptor isoform hub219.3 precursor 1.13 2.19
NM_006379_1 sema domain, immunoglobulin domain (ig), short basic domain, secreted, 
(semaphorin) 3c; sema3c
-0.69 0.62
NM_002546_1 osteoprotegerin; tnfrsf11b -1.03 0.49
Passage 5 vs passage 10 Acc.No
NM_019105_1 tenascin xb 0.85 1.80
List of differentially expressed genes after statistical analysis by modified version of the regularized t-test [64] (p < 0.05) for ten donors (passage 2 
vs. passage 5) and five donors (passage 5 vs. passage 10).Page 5 of 15
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differentiation were most similar to human osteoblasts
[see Additional file 18]. This observation could be con-
firmed by the comparison of the morphology of the two
cell types: Human osteoblasts isolated from hipbone rep-
resented non-mineralized osteoblasts with fibroblast-like
phenotype, morphologically similar to induced MSC on
day seven after induction.
Discussion
In this study we could show for the first time that MSC
maintain their undifferentiated phenotype after ex vivo
long-term expansion. The results of the microarray assays
showed that MSCs did not change significantly their gene
expression profiles during long-term expansion since only
nine out of almost 30.000 genes were differentially
expressed between passage 2 and passage 5 in ten donors.
In addition, no changes in the expression profiles after
additional 5 passages could be observed in five of the ten
donors. These surprising results can only be partially
explained by the limitations of the microarray technology.
Due to the lower sensitivity and uncomplete coverage of
the transcriptome, some genes required for stem cell
maintenance might have been missed. Additionally, indi-
vidual differences between the donors and slightly differ-
ent conditions during tissue extraction and sample
Expression view of all clusters calculated by k-means clusteringFigure 2
Expression view of all clusters calculated by k-means clustering. K-means clustering was performed for 1108 selected genes/
ESTs shown to be more than two fold up or down regulated in at least one time point during osteogenic differentiation. Genes 
were grouped in 12 clusters with distinct expression profiles. Relative expression levels (log2 ratios) are shown for each gene 
at different time points and for the mean expression values (magenta line).Page 6 of 15
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Summary of osteogenic development; a) Graphical summary of the 3 phases of osteogenic development merged with the time 
scale; b) Chosen clusters after k-means clustering describing each developmental phase merged with the expression matrix of 
distinct key regulators.
A) Phenotypic changes during osteogenic development
day of
osteogenic induction
  day 0  day 4     day 7    day 14   day 21 
X            X        X                     X                         X
 proliferation
matrix maturation
mineralization
B) Expression time-course of osteogenic regulator genes during distinct differentiation phases
 3)
 11)
  8) 
9)
  7)
12)
BMC Genomics 2007, 8:70 http://www.biomedcentral.com/1471-2164/8/70treatment could increase the number identified genes
which were otherwise filtered out during averaging. How-
ever, the microarray results were supported by the analy-
ses of the effects of extensive long-term ex vivo cultivation
of MSC on their proliferation capacity, their morphology,
surface marker profile, and differentiation ability. During
the long cultivation time we could observe, in concord-
ance with other groups [37,38], a progressive lost of pro-
liferation ability and a slight shift in the cell-morphology
of MSC of higher passage. However, their surface marker
profile determined by flow cytometry (CD44+, CD90+,
CD73+, CD105+, CD166+, CD45-, CD117-, HLA DR)
and by Real-time RT-PCR was not altered. Over and
above, the stem cell markers like CD90 and STRO1
showed stable expression levels, which further supports
our observation that MSC maintained their undifferenti-
ated phenotype and remained capable of osteogenic dif-
ferentiation during ex vivo expansion at all tested passages
(p2-p10).
Additionally to this clinically relevant evidence, we pro-
vide novel biological insights derived from the global
view of the molecular processes during osteogenic devel-
opment. First, we were able to illustrate the different
phases of osteogenic development in a human model.
Temporal expression of cell growth and osteoblast pheno-
type-related genes in a rodent model were first described
by Stein et al. [39]. In our study, using large-scale expres-
sion profiling of clinical samples we could associate gene
clusters to the three distinct phases of the development of
osteoblast phenotype: proliferation, matrix maturation
and mineralization.
Distribution of gene ontology (GO) terms regarding biological processes for genes in each clusterFigure 4
Distribution of gene ontology (GO) terms regarding biological processes for genes in each cluster. The GO terms listed here 
are those present in at least 5% of the genes within the cluster. In brackets are the number of genes with associated GO terms 
and the number of genes within the cluster.Page 8 of 15
(page number not for citation purposes)
BMC Genomics 2007, 8:70 http://www.biomedcentral.com/1471-2164/8/70Second, we could identify markers of late osteogenesis:
ID4, CRYAB and SORT1:
a) ID4 is one of the four members of the ID (inhibitor of
DNA binding) transcription factor family, which belongs
to the basic-helix-loop-helix (bHLH) family. The ID mem-
bers play a key role in differentiation processes and are
involved in cell cycle control and cellular senescence [40-
43]. It has been shown that ID proteins, by heterodimeri-
zation with bHLH proteins (MyoD, E12, E47), inhibit
their binding to DNA, thus acting as dominant negative
regulators, and have to be down-regulated to continue the
differentiation process [44,45]. To the best of our knowl-
edge only ID1, ID2 and ID3 have been identified as most
significantly up-regulated early targets of the osteogenic
BMP2, BMP6 and BMP8 [46]. In our study we provide evi-
dence that also ID4 exhibits a specific role during the oste-
ogenic differentiation.
b) The second identified gene is crystallin-αB (CRYAB).
Alpha crystallins are small heat shock proteins and com-
posed of two gene products: alpha-A and alpha-B, for
acidic and basic. Alpha-A is preferentially restricted to the
vertebrate eye lens where it maintains the transparency
Illustration of the TGF-β signaling pathway derived from KEGG database with mapped genes according to their expression level ( t least wo fold up or down regul te ); green = down-regulated genes, red = up-regul ted ge es and yellow = unregu-at d gen s; mapped gene  are at le st two-fold differentially expressFigu e 5
Illustration of the TGF-β signaling pathway derived from KEGG database with mapped genes according to their expression 
level (at least two fold up or down regulated); green = down-regulated genes, red = up-regulated genes and yellow = unregu-
lated genes; mapped genes are at least two-fold differentially expressed.Page 9 of 15
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expressed in many tissues and organs [47]. The here
observed up-regulation of CRYAB suggests an involve-
ment in osteogenic differentiation but its specific role is
still unknown. This involvement is supported by
Furushima et al. [48], who performed a linkage study with
knowledge-based candidate genes to detect genetic deter-
minants associated with OPLL (ossification of the poste-
rior longitudinal ligament of the spine), a predominant
myelopathy among Japanese. The candidate genes for
examination were obtained by cDNA microarray analysis
of gene expression profiles during osteoblastic differenti-
ation of MSC. Among the 24 genes identified in cDNA
microarray analysis which could be associated with bone
metabolism, CRYAB was the only gene which showed sig-
nificant evidence of linkage.
c) Further, we could show the role of sortilin1 during oste-
ogenic differentiation. Sortilin 1 (SORT1) represents a
multi-ligand type-1 receptor which binds a number of
unrelated ligands that participate in a wide range of cellu-
lar processes. The expression of SORT1 was increasing
until day seven and then slowly decreasing. Sortilin1, also
known as neurotensin receptor-3, is a glycoprotein origi-
nally purified from human brain [49]. The expression of
sortilin1 is ubiquitous; it has been observed in heart,
brain, placenta, lung, skeletal, muscle, pancreas, prostate,
testis, small intestine, thyroid, and spinal cord, whereas its
expression in bone marrow could not be detected [50].
The function of srotilin1 in bone metabolism is poorly
understood. Maeda et al. [51] reported first differential
expression during osteogenic differentiation and per-
formed further experiments, which showed that sortilin 1
is promoting extracellular matrix maturation. Our results
presented here strengthen this hypothesis, since sortilin 1
shows a similar expression progression as other well
known osteogenic genes, such as ALPL or BMPs.
In summary, we have identified by expression profiling
and confirmed by quantitative RT-PCR three markers of
late osteogenesis. Further studies are necessary to quantify
the expression of ID4, SORT-1 and CRYAB in primary
human osteoblasts and other cell types and to identify the
role of these genes in osteogenesis.
Third, by mapping the obtained expression data on
curated biomolecular pathways, we were able to illustrate
the distinct activation of the different Smad pathways
induced by BMPs, TGF-β and inhibin, which were sum-
marized as TGF-β pathways. The mapping of the expres-
sion data demonstrated that the fate of cell differentiation
was simultaneously controlled at three different points: 1)
BMP2, BMP6 and BMP8 activated the Smad-signaling
pathway, consisting of the main components Smad 1,
Smad 5 and Smad 8 resulting in osteoblast differentiation;
2) TGF-β2, regulating Smad 2 and Smad 4, was down reg-
ulated and the subsequent mechanisms were suppressed;
and 3) inhibin was, like TGF-β2, down regulated. These
findings have been confirmed by recent reports describing
the diverse Smad-signaling pathways, but have never been
illustrated in a general overview before this study [52-55].
Finally, the comparison of in vitro differentiated osteob-
lasts with in vivo developed osteoblasts on morphological
and genetic level proved the usefulness of MSC as in vitro
model for the investigation of the osteogenic develop-
ment.
Conclusion
The here presented results demonstrate that MSC repre-
sent a cell population which can be expanded ex vivo and
differentiated into osteoblasts. The genomic approach
presented here represents a powerful tool to systemati-
cally and comprehensively investigate therapeutic
approaches and hence, facilitate translational research on
stem cells. However, it should be pointed out that new
quality and safety standards have to be developed to guar-
antee risk free usage of ex vivo manipulated cell material
for future therapeutic applications.
Methods
Cultivation and ex vivo expansion of human bone 
marrow-derived MSC and normal human osteoblasts
The mononuclear cell fractions (MNC) were derived from
bone marrow from eleven different donors (Table 2), who
gave consent after full information and approval by the
hospital ethical committee (No. 12–091). All MNC were
isolated from bone marrow aspirates at iliac crest during
surgery. MNC were seeded at a density of 1 × 105 per cm2
and cultured for 24 hours. After these 24 hours non-
adherent cells were removed by medium exchange. The
adherent cells were cultured in expansion medium con-
taining DMEM (Invitrogen), 10% FBS (selected lot, Stem
Cell Technologies), 100 U/ml penicillin, 100 μg/ml strep-
tomycin and 2 mM L-glutamine under a humidified
atmosphere of 5% CO2 at 37°C. Medium was changed
three times a week. After reaching a confluence of 75–85%
the cells were detached with 0.05% trypsin/1 mM EDTA
and replated at density of 4 × 103cells/cm2. The cells were
expanded until the end of the tenth passage (correspond-
ing to 26 cell doublings).
The cells for the cultivation of normal human osteoblasts
derived from hipbone were obtained by PromoCell (Hei-
delberg, Germany). The cryopreserved normal human
osteoblasts were thawed and cultivated until the end of
the fourth passage following the protocols and media rec-
ommended by PromoCell.Page 10 of 15
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For determining the starting number of MSC in the mono-
nuclear cell fraction CFU-F assays were performed. MNC
from at least three donors were seeded in three concentra-
tions, 2*106, 1*106 and 0.5*106 cells per T25 flasks, and
incubated for 14 days in expansion medium without
medium exchange under a humidified atmosphere of 5%
CO2 at 37°C. After 14 days the cell suspension was
removed, the adherent cells were fixed with methanol,
dried and stained for 5 minutes with Giemsa staining
solution (VWR). After washing with distilled water the
colonies were counted and the human MSC frequency in
the MNC fraction was calculated.
Ex vivo differentiation of human bone marrow-derived 
MSC in osteoblasts and adipocytes
For the induction of osteogenesis MSC were seeded at a
density of 104 cells/cm2 in expansion medium. After 24
hours the differentiation was induced by medium
exchange. The osteogenic differentiation medium was
based on the expansion medium supplemented with 10
nM dexamethasone, 0.1 mM ascorbic-acid-2-phosphate
and 10 mM β-glycerophosphate. The adipogenic differenti-
ation medium contained in addition to the expansion
medium 0.1 μM dexamethasone, 50 μM indomethacin
and 5 μg/ml insulin. The media were changed three times
a week. Osteogenic differentiation was detected by Alka-
line Phosphatase assay (Sigma) and Alizarin Red S stain-
ing of mineralized matrix, whereas adipogenic
differentiation was detected by Oil Red O staining of the
adipocyte specific fat vacuoles.
The Alkaline Phosphatase assay was performed with the
Alkaline Phosphatase kit No. 85 purchased by Sigma fol-
lowing the manufacturers' instructions. For the Alizarin
Red S staining a 1% Alizarin Red S in 2% EtOH staining
solution was prepared. The medium was removed; the
cultures were washed twice with preheated 37°C PBS,
fixed with 10% formaldehyde for 10 minutes, washed
again with distilled water and incubated with the Alizarin
Red S staining solution for 5 minutes. After incubation the
staining solution was removed and the cultures were
washed 5 times with distilled water to get rid of excessive
color.
For the Oil Red O staining a 0.5% Oil Red O stock solution
in 2-Propanol was prepared. For the staining procedure
the stock solution was diluted 3:2 with distilled water, 10
minutes incubated at room temperature and filtrated by
using Whatmanpaper #1. The medium was removed; the
cells were washed with PBS, fixed with 10% formalin for
at minimum 30 minutes, and stained with the Oil Red O
staining solution for one hour.
Surface marker profiling by flow cytometry analysis
For flow cytometry analysis the cells were detached with
0.05% trypsin/EDTA and washed with PBS. 1 × 105 cells
per tube were blocked for 5 minutes with human AB
serum (Sigma) and stained for 15 minutes incubated in
an ice bath in the dark with direct PE or FITC conjugated
mouse anti-human monoclonal antibodies (Becton Dick-
inson) recognizing CD11b, CD34, CD38, CD44, CD45,
CD73, CD90, CD117 and HLA-DR. After antibody incu-
bation the cells were washed with PBS/sodium azide and
resuspended in PBS in the needed volume for analyzing.
5 minutes before the analysis 7-AAD (0.25 μg per test) was
applied to each sample for exclusion of dead cells. For
negative control immunoglobulin isotype incubation was
performed. FACS analyses were performed with FACS Cal-
ibur (Becton Dickinson).
Sample preparation – RNA isolation
Total RNA was isolated with TRIzol reagent (GibcoBRL-
Life Technologies) following the instructions of the man-
ufacturer. RNA concentration was determined by photo-
metric measurement. The RNA quality was analyzed by
Table 2: Clinical characteristics of the donors.
No. Sex Age Clinical diagnosis Therapy
1 f 64.1 Arthrosis of hip joint Total endoprothesis
2 f 49.5 Arthrosis of hip joint Total endoprothesis
3 f 56.0 Osteoporotic fracture Osteosynthesis
4 f 79.3 Arthrosis of hip joint Total endoprothesis
5 m 78.9 Avascular necrosis of 
femoral head
Total endoprothesis
6 m 46.1 Avascular necrosis of 
femoral head
Total endoprothesis
7 m 81.6 Arthrosis of hip joint Total endoprothesis
8 f 72.6 Arthrosis of knee joint Total endoprothesis
9 m 38.4 Arthrosis of hip joint Total endoprothesis
10 m 39.8 Arthrosis of hip joint Total endoprothesis
11 f 79.5 Arthrosis of knee joint Total endoprothesis
Sex, age, clinical diagnosis and therapy of the donors whose cells were used in this study.Page 11 of 15
(page number not for citation purposes)
BMC Genomics 2007, 8:70 http://www.biomedcentral.com/1471-2164/8/70Agilent 2100 Bioanalyzer RNA assays and evaluated by
calculating the ratio of the 28S and 18S ribosomal RNA
intensity peaks.
Microarray production
Human oligonucleotide microarrays were developed
using 29550 oligonucleotides derived from 30 K MWG
Human Oligo Set with 50 bp in length (provided by Prof.
Reinhard Kofler, Tyrolian Cancer Research Institute), and
dissolved in spotting buffer consisting of 3× SSC, 1.5 M
Betaine. Microarrays were produced by spotting the
reporters (including spotting buffer as negative control
and human genomic DNA as positive control) in 48
blocks onto an epoxy-coated glass slide (Nexterion)
resulting in 33456 features on a single high density array.
Reporter molecules were fixed to the slides by baking at
42°C for 8 h at 50% relative humidity. RefSeq IDs indi-
cate the genes represented by the oligonucleotides [see
Additional file 3].
Microarray hybridization procedure
The used labeling and hybridization procedures were
based on those developed at The Institute for Genomic
Research (TIGR) and modified at the Institute for Genom-
ics and Bioinformatics [see Additional file 4 and 5]. All
hybridizations were repeated with reversed dye assign-
ment (dye-swap). After hybridization slides were scanned
with GenePix 4000B microarray scanner (Axon Instru-
ments) at 10 μm resolution. Identical settings were used
for scanning the corresponding dye-swapped hybridized
slides. The resulting TIFF images for each of the two fluor-
ophores were analyzed with GenePix Pro 4.1 (Axon
Instruments).
Bioinformatics analyses
After image acquisition and filtering the data for low
intensity, inhomogeneity and satured spots, the results
files were normalized with the in-house developed soft-
ware ArrayNorm [56]. After background correction the
data sets were normalized by global-mean and dye-swap
pairs or LOWESS-subgrid normalization. The obtained
result files were used for further analyses such as cluster
analysis [57], GO annotation [58] and pathway analyses
[59]. Cluster analyses were performed with the Genesis
software tool using k-means clustering function [28]. The
number of clusters was varied from k = 1 to k = 15 and pre-
dictive power was analyzed with the figure of merit [60].
Subsequently, k = 12 was found optimal. GO annotation
was performed on differentially expressed genes. Pathway
analyses were performed with the in house developed
Pathway Explorer software [59] which mapped the RefSeq
IDs from the results file (cut-off level for differentially
expressed genes: log2 ratio > 1) on public available path-
ways like Biocarta [61] and KEGG database [30]. All exper-
imental parameters, images, raw and transformed data
were uploaded to the microarray database MARS [62] and
submitted via MAGE-ML export to a public repository
(ArrayExpress, accession numbers A-MARS-2, E-MARS-3,
E-MARS-4, E-MARS-5, and E-MARS-6) [63].
Real-time RT PCR
The same sources of total RNA used in the microarray
experiments were used for the data validation by RT-PCR.
The SuperScript™ II First Strand Synthesis System for RT
PCR (Invitrogen) was used to synthesize cDNA of 5 μg
RNA following manufacturers' recommendations. RNA
contaminating genomic DNA was removed by treatment
with DNAse I amplification grade (Invitrogen). The
SuperScript™ II product was diluted 1:25 and directly used
for the RT-PCR.
The RT-PCR assays were performed using the Eurogentec
qPCR™ Mastermix Plus for Sybr™ Green I following man-
ufacturer's recommendations. NO-reverse transcription
Controls (No-RT) and No-Template Controls (NTC) were
performed for each RNA type and primer pair. Cycling
conditions on the ABI Prism 7000: 2 minutes at 50°C, 10
minutes at 95°C, 40 × (15 seconds at 95°C, 1 minute at
60°C) and the dissociation protocol at 60°C was added.
For each sample RNA two cDNAs were prepared but in
independent reverse transcription reactions. Each gene
was tested with both cDNAs and the cDNAs were also
tested in duplicate on one plate. Hence, four RT-PCR reac-
tions were performed for the examination of one single
gene. Further, the sample cDNA and the corresponding
reference cDNA were tested on one plate, so that the data
can be compared directly.
For normalization of the data the average of the expres-
sion level of four house-keeping genes, GAPDH, HPRT,
beta-actin and beta-tubulin, was used.
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